|
|
 Previous Article | Table of Contents | Next Article 
Recipient immune-competent T lymphocytes can survive intensive conditioning
for bone marrow transplantation
A Butturini, RC Seeger and RP Gale
Bone marrow transplantation is usually preceded by intensive chemotherapy
and radiation therapy designed to completely eliminate recipient
immune-competent cells that might reject the donor bone marrow. We show
that seven of 14 bone marrow transplant recipients who received intensive
conditioning retained circulating T lymphocytes that proliferate after
incubation with interleukin 2 and phytohemagglutinin and function as
effector cells in an in vitro model of graft rejection. These T cells may
mediate graft rejection.
Volume 68,
Issue 4,
pp. 954-956,
10/01/1986
Copyright © 1986 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. K. Gandhi, M. R. Wills, G. Okecha, E. K. Day, R. Hicks, R. E. Marcus, J. G. P. Sissons, and A. J. Carmichael
Late diversification in the clonal composition of human cytomegalovirus-specific CD8+ T cells following allogeneic hemopoietic stem cell transplantation
Blood,
November 1, 2003;
102(9):
3427 - 3438.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. A. Bethge, D. S. Wilbur, R. Storb, D. K. Hamlin, E. B. Santos, M. W. Brechbiel, D. R. Fisher, and B. M. Sandmaier
Selective T-cell ablation with bismuth-213-labeled anti-TCR{alpha}{beta} as nonmyeloablative conditioning for allogeneic canine marrow transplantation
Blood,
June 15, 2003;
101(12):
5068 - 5075.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Gur, R. Krauthgamer, A. Berrebi, T. Klein, A. Nagler, A. Tabilio, M. F. Martelli, and Y. Reisner
Tolerance induction by megadose hematopoietic progenitor cells: expansion of veto cells by short-term culture of purified human CD34+ cells
Blood,
May 13, 2002;
99(11):
4174 - 4181.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. T. Ho and R. J. Soiffer
The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation
Blood,
December 1, 2001;
98(12):
3192 - 3204.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Verfuerth, K. Peggs, P. Vyas, L. Barnett, R. J. O'Reilly, and S. Mackinnon
Longitudinal monitoring of immune reconstitution by CDR3 size spectratyping after T-cell-depleted allogeneic bone marrow transplant and the effect of donor lymphocyte infusions on T-cell repertoire
Blood,
June 15, 2000;
95(12):
3990 - 3995.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. R. Spitzer
Nonmyeloablative Allogeneic Stem Cell Transplant Strategies and the Role of Mixed Chimerism
Oncologist,
June 1, 2000;
5(3):
215 - 223.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
T. Guillaume, D. B. Rubinstein, and M. Symann
Immune Reconstitution and Immunotherapy After Autologous Hematopoietic Stem Cell Transplantation
Blood,
September 1, 1998;
92(5):
1471 - 1490.
[Full Text]
[PDF]
|
|
|
|
|
